Slade to purchase Fresenius Kabi oncology compounding business

handshake: Medicines australia/Govt letter of agreement
Slade Pharmacy Services has entered into agreements with Fresenius Kabi to purchase its Oncology Compounding Business in Australia. This includes all the TGA-licenced compounding facilities in Queensland, NSW and Victoria. Slade says it intends to retain the staff currently employed at the facilities. Slade currently operates a TGA-licenced manufacturing facility in Victoria and services both

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Just the facts: Medicines Australia publishes meds trends book
Next Pharmacy flu jabs confusing, won't increase uptake: UK GPs